Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to… read more.
In a global perspective, depression is the leading cause of ill health and disability. More than 264 million people are affected and at least 25 per cent of… read more.
ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) from AstraZeneca in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban… read more.
Cancer that spreads to the brain from another part of the body such as lung or breast is called a metastatic brain tumor. As metastatic brain tumors grow,… read more.
The U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the pivotal Phase 1/II MajesTEC-1 study showing the sustained efficacy and safety of Tecvayli (teclistamab-cqyv) in… read more.
GSK announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by… read more.
Treatment with the diabetes drug metformin immediately after testing positive for the SARS-CoV-2 virus lowers the risk of developing long COVID by 41%. Researchers reported this finding on… read more.
Novartis presents positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting . Data showed that… read more.
Pre-term and low birthweight infants have fewer fractures in childhood than full-term and normal-weight newborns, according to a new a study from the University of Eastern Finland and… read more.
In a new study, titled “Acceptability and Usability of a Wearable Device for Sleep Health Among English- and Spanish-Speaking Patients in the Safety Net: Qualitative Analysis,” researchers found… read more.
Amgen announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
